Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04907539
Recruitment Status : Not yet recruiting
First Posted : May 28, 2021
Last Update Posted : July 7, 2021
Sponsor:
Information provided by (Responsible Party):
Redx Pharma Plc

Brief Summary:
This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with Nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: RXC004 Biological: Nivolumab Biological: Denosumab Phase 2

Detailed Description:

The study is composed of two arms, RXC004 monotherapy (Arm A) and RXC004 in combination with Nivolumab (Arm B). 20 evaluable patients will be enrolled in Arm A and 20 eligible patients in Arm B.

The study will initially open with Arm A; Arm B will be opened once a recommended Phase II dose (RP2D) for RXC004 in combination with Nivolumab is established in the phase I dose escalation study (NCT03447470).

Patients in Arm A may be treated with RXC004 + Nivolumab if they have progressive disease on the 8 week scan (if Arm B is open at the time of progression).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination With Nivolumab, in Patients With Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer Who Have Progressed Following Therapy With Current Standard of Care (PORCUPINE)
Estimated Study Start Date : August 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Arm A: RXC004 monotherapy

Patients will receive RXC004 (1.5 mg once daily [QD], orally).

Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression).

Drug: RXC004

RXC004 will be administered orally, 1.5 mg QD

Dose Formulation: 0.5 mg or 1 mg capsules.


Biological: Denosumab

Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.

Use: Prophylactic


Experimental: Arm B: RXC004 + Nivolumab

Patients will receive RXC004 (1.5 mg QD, orally) in combination with Nivolumab (480 mg every 4 weeks [q4w], intravenous [IV] infusion).

Arm B will be opened once a RP2D for RXC004 in combination with Nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with Nivolumab will be based on data from the phase 1 study (NCT03447470).

Drug: RXC004

RXC004 will be administered orally, 1.5 mg QD

Dose Formulation: 0.5 mg or 1 mg capsules.


Biological: Nivolumab
Nivolumab will be administered via IV infusion, 480 mg q4w.

Biological: Denosumab

Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.

Use: Prophylactic





Primary Outcome Measures :
  1. RXC004 Monotherapy: Disease control rate (DCR) using each patients Best Overall Response (BOR) according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1) [ Time Frame: Up to 20 months ]
    To assess the anti-tumour activity of RXC004 monotherapy. DCR is defined as the proportion of patients with a BOR of either complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks post baseline.

  2. RXC004 + Nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1 [ Time Frame: Up to 20 months ]
    To assess the anti-tumour activity of RXC004 +Nivolumab. ORR is defined as the proportion of patients with a BOR of CR or PR, based on local investigator assessment, as defined in RECIST 1.1.


Secondary Outcome Measures :
  1. Percentage change in the sum of target lesions [ Time Frame: Up to 24 months ]
    To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + Nivolumab. Percentage change in tumour size will be derived at each visit by the percentage change from baseline in the sum of diameters of target lesions. The best percentage change in tumour size will be the patients value representing the largest decrease (or smallest increase) from baseline in tumour size.

  2. Duration of response (DoR) [ Time Frame: Up to 24 months ]
    To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + Nivolumab. The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. If a patient does not progress following a response, then their DOR will be censored at the progression free survival (PFS) censoring time.

  3. Progression free survival (PFS) [ Time Frame: From first dose of study treatment until the date of disease progression or death (Up to 24 months) ]
    To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + Nivolumab. PFS is defined as the time from first dose of study treatment until the date of disease progression or death (by any cause in the absence of progression).

  4. RXC004 Monotherapy: ORR using investigator assessments according to RECIST 1.1 [ Time Frame: Up to 24 months ]
    To further assess the preliminary efficacy of RXC004 monotherapy. ORR is defined as the proportion of patients with a BOR of CR or PR, based on local investigator assessment, as defined in RECIST 1.1.

  5. RXC004 + Nivolumab Combination: DCR using investigator assessments according to RECIST 1.1 [ Time Frame: Up to 24 months ]
    To further assess the preliminary efficacy of RXC004 + Nivolumab. DCR is defined as the proportion of patients with a BOR of either CR, PR or SD for at least 16 weeks post baseline.

  6. Overall survival (OS) [ Time Frame: Up to 24 months ]
    To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + Nivolumab. OS is defined as the time from first day of study treatment until death due to any cause.

  7. Maximum observed plasma concentration (Cmax) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the pharmacokinetic (PK) of RXC004 in monotherapy and in combination with Nivolumab.

  8. Time to Cmax (tmax) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  9. Minimum observed concentration across the dosing interval (Cmin) [ Time Frame: At each treatment cycle (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  10. Terminal rate constant (λz) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  11. Terminal half-life (t½) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  12. Area under the plasma concentration-time curve from zero to infinity (AUC0-∞) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  13. Total plasma clearance after oral administration (CL/F) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  14. Apparent volume of distribution after oral administration (Vz/F) [ Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length) ]
    To assess the PK of RXC004 in monotherapy and in combination with Nivolumab.

  15. Number of patients with adverse events (AEs) [ Time Frame: From time of signature of informed consent form throughout the treatment period and until 30 days after the last dose of RXC004 (for RXC004 monotherapy only) or 90 days after the last dose of Nivolumab (for RXC004 + Nivolumab) (up to 24 months) ]
    To assess the safety and tolerability profile of RXC004 monotherapy and RXC004 + Nivolumab combination



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological documentation of metastatic (Stage IV) Colorectal cancer (CRC) and

    1. Documented tumour tissue aberration in RNF43 and/or RSPO
    2. Documented confirmation of microsatellite stable (MSS) status
  • Patients must have had documented RECIST1.1 defined radiological progression following a minimum of 1 prior SOC treatment regimen for metastatic disease
  • Eastern Cooperative Oncology Group performance status 0 or 1
  • At least one lesion that is measurable by RECIST 1.1 at baseline
  • Patients must have at least one lesion suitable for biopsy at screening and be willing to provide mandatory tumour biopsy samples
  • Patients with adequate organ functions
  • Female patients of childbearing potential must have a negative pregnancy test prior to start of dosing
  • Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 5 months after the last dose of study drug.

Exclusion Criteria:

  • Prior therapy with a compound of the same mechanism of action as RXC004
  • Patients at higher risk of bone fractures
  • Any known uncontrolled inter-current illness or persistent clinically significant toxicity related to prior anti-cancer treatment
  • Patients who have any history of an active (requiring treatment) other malignancy within 2 years of study entry
  • Patients with known or suspected brain metastases
  • Use of anti-neoplastic agents, immunosuppressants and other investigational drugs
  • Patients with a known hypersensitivity to any RXC004 excipients
  • Patients with a contra-indication for denosumab treatment
  • Patients who are pregnant or breast-feeding

For patients on RXC004 + Nivolumab combination treatment (Arm B or Arm A RXC004 + Nivolumab treatment phase):

  • Patients with any contraindication to the use of Nivolumab
  • Patients with active or prior documented autoimmune or inflammatory disorders within the past 5 years
  • Patients with active infections, including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus
  • Use of any live vaccines against infectious diseases (e.g., influenza, varicella) within 4 weeks (28 days) of initiation of study treatment
  • Patients with a history of allogeneic organ transplant or active primary immunodeficiency
  • Patients with a known hypersensitivity to Nivolumab or any of the excipients of the product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04907539


Contacts
Layout table for location contacts
Contact: Craig Tilston +44(0) 1625 469908 c.tilston@redxpharma.com
Contact: Richard Armer +44 (0)7733 361689 r.armer@redxpharma.com

Locations
Layout table for location information
United Kingdom
Beatson West of Scotland Cancer Centre - Oncology
Glasgow, Scotland, United Kingdom, G12 0YN
Sponsors and Collaborators
Redx Pharma Plc
Layout table for additonal information
Responsible Party: Redx Pharma Plc
ClinicalTrials.gov Identifier: NCT04907539    
Other Study ID Numbers: RXC004/0002
First Posted: May 28, 2021    Key Record Dates
Last Update Posted: July 7, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Redx Pharma Plc:
Open label
RXC004
Nivolumab
Ring finger protein 43
R-spondin
Efficacy
Safety
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Denosumab
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs